What is the financial performance of Johnson and Johnson? (2024)

What is the financial performance of Johnson and Johnson?

Johnson & Johnson reported earnings results for the third quarter and nine months ended October 01, 2023. For the third quarter, the company reported sales was USD 21,351 million compared to USD 19,996 million a year ago. Net income was USD 26,028 million compared to USD 4,458 million a year ago.

Is Johnson and Johnson financially healthy?

Financial Health criteria checks 6/6

Johnson & Johnson has a total shareholder equity of $71.2B and total debt of $29.9B, which brings its debt-to-equity ratio to 42%. Its total assets and total liabilities are $166.1B and $94.8B respectively. Johnson & Johnson's EBIT is $22.0B making its interest coverage ratio -45.

What are the financial projections for Johnson and Johnson?

JNJ Sales Forecast

Next quarter's sales forecast for JNJ is $21.46B with a range of $21.11B to $22.20B. The previous quarter's sales results were $21.39B. JNJ beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.78% of the time in the same period.

Is Johnson & Johnson profitable?

Johnson & Johnson gross profit for the twelve months ending September 30, 2023 was $66.515B, a 6.25% increase year-over-year. Johnson & Johnson annual gross profit for 2022 was $63.854B, a 0.1% decline from 2021. Johnson & Johnson annual gross profit for 2021 was $63.92B, a 18.03% increase from 2020.

What is Johnson and Johnson revenue for 2023?

Johnson & Johnson revenue for the quarter ending September 30, 2023 was $21.351B, a 6.78% increase year-over-year. Johnson & Johnson revenue for the twelve months ending September 30, 2023 was $99.128B, a 7.46% increase year-over-year. Johnson & Johnson annual revenue for 2022 was $94.943B, a 1.25% increase from 2021.

Why is J&J stock so low?

The sprawling litigation over its talc products, in particular, took a turn for the worse in late July. Still, much of the drop likely stems from a broader malaise that's afflicted pharmaceutical and medical device stocks this year. More than one malady has struck the healthcare sector, and there's no panacea in sight.

Is Johnson and Johnson in debt?

Total debt on the balance sheet as of September 2023 : $29.92 B. According to Johnson & Johnson's latest financial reports the company's total debt is $29.92 B.

What is the outlook for Johnson and Johnson in 2023?

The drugmaker raised that revised outlook on Tuesday: J&J expects 2023 sales of $83.6 billion to $84 billion, compared with previous guidance of $83.2 billion to $84 billion in August. J&J also expects adjusted earnings per share of $10.07 to $10.13, up from a previous forecast of $10.00 to $10.10.

Who are the biggest investors in Johnson and Johnson?

Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Jpmorgan Chase & Co, and Northern ...

Is Johnson and Johnson a good stock to buy 2023?

Johnson & Johnson (NYSE: JNJ) stock had a disappointing 2023, seeing its share price fall by 11%. In the year before that, the stock only generated a modest return of 3%. It's fair to say J&J has been an underwhelming investment.

Who owns the largest share of Johnson & Johnson?

Who owns Johnson & Johnson? Johnson & Johnson (NYSE: JNJ) is owned by 68.01% institutional shareholders, 0.19% Johnson & Johnson insiders, and 31.80% retail investors. Vanguard Group Inc is the largest individual Johnson & Johnson shareholder, owning 229.29M shares representing 9.52% of the company.

How much does the CEO of Johnson and Johnson make a year?

Johnson & Johnson CEO Joaquin Duato received $13.1 million in total compensation in 2022, according to a company financial filing this week. The pay is slightly down from the $13.8 million Duato brought home in 2021 and down from the $15.6 million he made in 2020.

Is Johnson and Johnson a safe investment?

Lately, J&J stock has been trading for 14.8x the midpoint of management's adjusted earnings expectation for 2024. This price is more than fair for a company that grew adjusted earnings by a double-digit percentage last year and could continue reporting gains at a high single-digit percentage in the years ahead.

Why is JNJ stock tanking?

Key Points. Johnson & Johnson edged out estimates and delivered in-line guidance for 2024. Concerns about legal settlements and competition for drug Stelara seemed to weigh on the stock.

What product makes Johnson and Johnson the most money?

The most popular consumer brands include Band-Aids, Tylenol and Johnson's Baby Powder. Still, the bulk of J&J's revenue comes from prescription drugs and medical devices.

How many employees does J&J have?

Every day, our more than 150,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.

Is JNJ going to split into two companies?

Why Johnson & Johnson is splitting itself into two publicly traded companies. Johnson & Johnson, the biggest pharmaceutical company in the U.S. based on market cap, announced in November 2021 it plans to spin off its consumer business into a new publicly traded company by November 2023.

Why is JNJ being sued?

NEW YORK, Dec 29 (Reuters) - A federal judge said Johnson & Johnson (JNJ. N) , opens new tab shareholders may pursue as a class action their lawsuit accusing the company of fraudulently concealing how its talc products were contaminated by cancer-causing asbestos.

Is JNJ a buy or hold?

Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 40 buy ratings, 34 hold ratings, and 1 sell ratings.

Is Johnson and Johnson losing money?

Investors in Johnson & Johnson had a tough year, with a total loss of 8.7% (including dividends), against a market gain of about 14%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period.

Is Johnson and Johnson a strong company?

With its wide array of medical, consumer health, and pharmaceutical products, Johnson & Johnson consistently generates strong cash flows. Coupled with its impressive 61-year history of dividend growth and infrequent share price drops, the current dip likely offers a compelling buying opportunity.

Is Johnson and Johnson a risky stock?

Johnson Johnson Investment Opportunity

Johnson Johnson has a volatility of 0.81 and is 1.25 times more volatile than NYSE Composite. 7 of all equities and portfolios are less risky than Johnson Johnson.

What are the challenges faced by J&J?

J&J is facing more than 38,000 lawsuits alleging that the company's talc products, including its Baby Powder, were contaminated by asbestos and caused cancers including ovarian cancer and mesothelioma.

What will Johnson and Johnson share price be in 2025?

The Johnson & Johnson stock prediction for 2025 is currently $ 165.31, assuming that Johnson & Johnson shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 5.70% increase in the JNJ stock price.

What will the stock price of Johnson and Johnson be in 2030?

Johnson and Johnson stock prediction

The site said the JNJ share prices could exceed $250 next year, with an average price of $269.53 in 2023, $259.94 in 2024, $267.41 in 2025, $267.92 in 2026, $262.98 in 2027, $246.29 in 2028, $230.15 in 2029 and $197.04 in 2030.

Popular posts
Latest Posts
Article information

Author: Trent Wehner

Last Updated: 15/12/2023

Views: 6638

Rating: 4.6 / 5 (56 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Trent Wehner

Birthday: 1993-03-14

Address: 872 Kevin Squares, New Codyville, AK 01785-0416

Phone: +18698800304764

Job: Senior Farming Developer

Hobby: Paintball, Calligraphy, Hunting, Flying disc, Lapidary, Rafting, Inline skating

Introduction: My name is Trent Wehner, I am a talented, brainy, zealous, light, funny, gleaming, attractive person who loves writing and wants to share my knowledge and understanding with you.